We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
BRISBANE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual...
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
TPST-1120, a first-in-class, oral, selective PPARโบ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized...
Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1 | -3.0303030303 | 3.3 | 3.43 | 3.17 | 318482 | 3.28643672 | CS |
4 | -0.34 | -9.60451977401 | 3.54 | 3.6499 | 3.12 | 301132 | 3.29472007 | CS |
12 | -0.18 | -5.32544378698 | 3.38 | 6 | 3.0611 | 833432 | 4.40860207 | CS |
26 | 0.12 | 3.8961038961 | 3.08 | 6 | 2.88 | 854763 | 4.18237673 | CS |
52 | 1.74 | 119.178082192 | 1.46 | 9.77 | 0.17 | 3160694 | 5.85132938 | CS |
156 | -10.61 | -76.8283852281 | 13.81 | 41 | 0.17 | 1185810 | 6.37376312 | CS |
260 | -10.61 | -76.8283852281 | 13.81 | 41 | 0.17 | 1185810 | 6.37376312 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions